Received Jun 19, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
2nd dose longer than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. Previously administered products included shingrix (received 1st dose on unknown date more than 5 years ago). On 11-JUN-2026, the patient received the 2nd dose of Shingrix. On 11-JUN-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 2nd dose longer than recommended interval). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date 16-JUN-2026 The reporter asked if we give another shot now was it considered 2nd shot. The reporter consented to follow up. No other information available